InvestSMART

Emyria Limited (ASX: EMD) - Announcements

- Current share price for EMD : $0.047

ASX company news and announcements for Emyria Limited (EMD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Emyria Limited (EMD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Emyria Limited (EMD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Emyria Limited (EMD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$38 Notification of cessation of securities - EMD 18 Oct 2021 5:54PM $0.225 $0.047 fallen by 79.11%
$38 Notification of cessation of securities - EMD 18 Oct 2021 5:54PM $0.225 $0.047 fallen by 79.11%
$38 Notification regarding unquoted securities - EMD 8 Oct 2021 11:05AM $0.220 $0.047 fallen by 78.64%
$38 Emyria selected to join Palantirs Foundry Builders Program 7 Oct 2021 10:04AM $0.205 $0.047 fallen by 77.07%
$38 EMD Welcomes TGA-Commissioned Report on MDMA and Psilocybin 1 Oct 2021 9:08AM $0.230 $0.047 fallen by 79.57%
$38 Annual Report to shareholders 1 Oct 2021 8:59AM $0.230 $0.047 fallen by 79.57%
$38 Appendix 4G 30 Sep 2021 6:35PM $0.230 $0.047 fallen by 79.57%
$38 Letter to Shareholders - Annual General Meeting 30 Sep 2021 6:29PM $0.230 $0.047 fallen by 79.57%
$38 Notice of Annual General Meeting/Proxy Form 30 Sep 2021 6:28PM $0.230 $0.047 fallen by 79.57%
$38 Lifesciences Webinar Presintation 28 Sep 2021 10:13AM $0.230 $0.047 fallen by 79.57%
$38 Novel MDMA Analogue Screening Program Advanced 22 Sep 2021 9:27AM $0.220 $0.047 fallen by 78.64%
$38 Notification regarding unquoted securities - EMD 22 Sep 2021 9:24AM $0.220 $0.047 fallen by 78.64%
$38 Emyria Expands Psychiatry Advisory for Psychedelics and MDMA 16 Sep 2021 9:13AM $0.235 $0.047 fallen by 80%
$38 MDMA-analogues Show Promise for Parkinson's Disease 1 Sep 2021 9:14AM $0.230 $0.047 fallen by 79.57%
$38 Appendix 4E and Full Year Statutory Accounts 31 Aug 2021 7:12PM $0.230 $0.047 fallen by 79.57%
$38 Annual General Meeting 31 Aug 2021 6:22PM $0.230 $0.047 fallen by 79.57%
$38 Emyria Engages Calvert Labs for Preclinical CBD studies 27 Aug 2021 9:13AM $0.195 $0.047 fallen by 75.90%
$38 Emyria Drug Development Overview and Webinar 23 Aug 2021 9:11AM $0.175 $0.047 fallen by 73.14%
$38 Emyria Appoints Expert Neuropharmacologist for MDMA Program 20 Aug 2021 8:45AM $0.185 $0.047 fallen by 74.59%
$38 Emyria Executes Pure CBD Agreement with AltaSciences 13 Aug 2021 8:45AM $0.190 $0.047 fallen by 75.26%
$38 CAN: Cann and Emyria mutually end collaboration 13 Aug 2021 8:37AM $0.190 $0.047 fallen by 75.26%
$38 Emyria and Cann Mutually End Collaboration 13 Aug 2021 8:37AM $0.190 $0.047 fallen by 75.26%
$38 Emyria to Develop Novel Psychedelics Pipeline with UWA 5 Aug 2021 9:17AM $0.175 $0.047 fallen by 73.14%
$38 Appendix 4C - Quarterly 28 Jul 2021 9:26AM $0.180 $0.047 fallen by 73.89%
$38 Principal Investigator Appointed to lead Emyria MDMA trial 29 Jun 2021 8:44AM $0.175 $0.047 fallen by 73.14%

401 - 425 of 554 results

Page 17 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.